Does radiation treatment delay affect survival in glioblastoma by Robe, Pierre et al.
519Abstracts / Surgical Neurology 72 (2009) 515–529Results: In all patients complete resection was achieved without neurological
complications. Histological examination revealed a papillary tumor in the first
case and a PNET in the second. The third patient had a recurrent colloid cyst.
Conclusion: Tumors located in the posterior part of the third ventricle are
challenging for the neurosurgeon. A transcortical interthalamo-trigonal
approach provides excellent access to this region allowing safe and
complete resection.
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Validation of RPA classification as a prognostic tool in 117 patients
with relapsed high grade glioma, vaccinated at time of recurrence
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bLaboratory of Experimental Immunology, University Hospitals Leuven,
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Introduction: Recursive Partitioning Analysis (RPA) in newly diagnosed
High Grade Glioma (HGG) patients has originally been validated by RTOG
as a prognostic tool. It classifies patients into 6 prognostic classes based on
age, pathology, performance status, mental status, extent of surgical
treatment and intensity of radiation therapy. We aimed to validate this
classification as a prognostic tool in 117 patients with a relapsed HGG, re-
operated and vaccinated at recurrence.
Material and methods: One hundred seventeen patients with a relapsed
HGG were re-operated and vaccinated using autologous dendritic cell-
based vaccines. After re-operation and before vaccination, each patient was
classified according to the RPA classes I to VI. The prognostic value of the
RPA classification was assessed after log rank analysis creating Kaplan
Meier overall survival (OS) estimates.
Results:Median OS after the pre-vaccine re-operation for RPA class I to VI
patients was not yet reached (N36 months, n = 4), 14.2 months (n = 10),
14 months (n = 28), 10.6 months (n = 51), 6 months (n = 15) and 4 months
(n = 9) respectively. At time of last follow-up, 75%, 50%, 35.7%, 11.7%,
0% and 0% of patients from RPA class I to VI respectively are still alive.
These differences in OS are highly significant (P b .0001).
Conclusion: We validated the original RTOG RPA classification as a good
prognostic tool in a large group of patients with relapsed HGG, re-operated
and vaccinated at time of recurrence.
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Treatment of acromegaly, results of 16 years experience
D'Haens J, MD, Vanrompaey K, MD, Ates R, MD, Moens M, MD, Ampe B,
MD, Lesage G, MD, Haentjens P, MD, Poppe Kris, MD, Velkeniers B, MD
[UZ Brussel, VUB]
Introduction: We report our experience in the treatment of 34 patients
suffering from acromegaly and treated in our institution between 1993 and
2008. The first line treatment was always surgery. Repeated surgery,
radiation therapy and medical treatment were considered in patients
showing no remission after surgery.
Material and methods: Before 2000, two patients underwent first cranial
surgery and 16 others underwent first microscopic transsphenoidal surgery
followed by transcranial surgery in one patient and by endoscopic surgery
in two others. From 2001 sixteen other patients underwent endoscopictransnasal surgery as first treatment, followed by transcranial surgery in
two of them. Remission was assessed by normalisation of both serum GH
and IGF-I and the suppression of GH (b1 ng/ml) after Oral Glucose
Tolerance Test.
Mean follow up period was 57 months.
Results: Overall remission rate with surgery alone was 19/34 (56%). Cure
rates in non invasive adenomaswas 80%and only 13% in invasive adenomas.
Recurrences after remission were observed in 6 cases (31, 5%).
Treatment of patients without remission after surgery included radiation
therapy and/or medical therapy. Ten patients out of 17 could be controlled for
their disease with these additional therapeutic modalities. The total number of
patients under control was 29/34 (85%). There was no mortality. Complica-
tions were limited to one epistaxis after microscopic transsphenoidal surgery
and one CSF leak treated with lumbar drainage after endoscopic surgery.
Conclusion: High recurrence rates of acromegalic disease were observed,
even using strict criteria for remission. Surgery alone gave satisfactory
results in non invasive adenomas, but additional treatments were required in
most of the invasive lesions.
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Does radiation treatment delay affect survival in glioblastoma?
Robe PA, MD, Nguyen-Khac M, MD, Lenelle J, MD, Stevenaert A, MD,
Kascthen B, MD, Dubuisson A, MD, Scholtes F, MD, Racaru T, MD,
Coucke Ph, MD, Martin DH, MD [CHU Liège]
Introduction: Recent literature suggests that delaying the initiation of
radiation therapy after surgery for malignant glioma significantly worsens
patients survival. These data are however based on retrospective studies of
heterogeneous series of patients and can only be applied cautiously to other
practices.
Material and methods: In order to analyze this relationship in our
institution, we reviewed the charts of 161 patients who were fully treated at
the Liège University Hospital for a histologically proven supratentorial de
novo glioblastoma multiforme (WHO grade 4) between January 1997 and
April 2008. Survival analyses were performed using the GraphPad and
Statview softwares.
Results: Of these patients, 22 (13.7%) died prior to the initiation of radiation
therapy or refused further therapy (Survival range: 1-190 days). Among the
remaining 139 patients, accurate data regarding radiation therapy specifics
and survival were obtained for 121 patients (87%). Radiation therapy was
initiated within 1 month from diagnostic in 103 of these patients, and
delayed by more than 31 days in 18 patients (14.8%). The median survival of
these two groups of patients differed by ∼17 weeks in favor of patients
treated within 1 month of surgery (Hazard Ratio: 1.7, 95% CI: 0.87 to 3.41).
Conclusion: The influence of age, KPS, dose and selection bias on the
significance of this result will be discussed, as well as the rationale to minimize
the delay between surgery and radiation treatment in de novo glioblastoma.
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Tumor-like MRS and PET findings in a case of radiation-induced
brain necrosis, away from any tumor: an intriguing case report
Nguyen-Khac MT, MD, Hustinx R, MD, Deprez M, MD, Tshibanda JF, MD,
Lefebvre Ph, MD, Martin DH, MD, Robe PA, MD [CHU Liège]
Introduction: Most data regarding the imaging characteristics of radiation
necrosis stem from patients who previously presented with a tumor ay the
